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Psycho-education with problem solving (PEPS)
therapy for adults with personality disorder:
A pragmatic multi-site community-based
randomised clinical trial
Mary McMurran1*, Mike J Crawford3, Joseph G Reilly4, Paul McCrone5, Paul Moran5, Hywel Williams2,
Clive E Adams1, Conor Duggan1, Juan Delport6, Diane Whitham2 and Florence Day2
Abstract
Background: Impairment in social functioning is a key component of personality disorder. Therefore psycho-
education and problem solving (PEPS) therapy may benefit people with this disorder. Psycho-education aims to
educate, build rapport, and motivate people for problem solving therapy. Problem solving therapy aims to help
clients solve interpersonal problems positively and rationally, thereby improving social functioning and reducing
distress. PEPS therapy has been evaluated with community adults with personality disorder in an exploratory trial.
At the end of treatment, compared to a wait-list control group, those treated with PEPS therapy showed better
social functioning, as measured by the Social Functioning Questionnaire (SFQ). A definitive evaluation is now being
conducted to determine whether PEPS therapy is a clinically and cost-effective treatment for people with
personality disorder
Methods: This is a pragmatic, two-arm, multi-centre, parallel, randomised controlled clinical trial. The target
population is community-dwelling adults with one or more personality disorder, as identified by the International
Personality Disorder Examination (IPDE). Inclusion criteria are: Living in the community (including residential or
supported care settings); presence of one or more personality disorder; aged 18 or over; proficiency in spoken
English; capacity to provide informed consent. Exclusion criteria are: Primary diagnosis of a functional psychosis;
insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and assessments;
currently engaged in a specific programme of psychological treatment for personality disorder or likely to start
such treatment during the trial period; currently enrolled in any other trial. Suitable participants are randomly
allocated to PEPS therapy plus treatment as usual (TAU) or TAU only. We aim to recruit 340 men and women. The
primary outcome is social functioning as measured by the SFQ. A reduction (i.e., an improvement) of 2 points or
more on the SFQ at follow-up 72 weeks post-randomisation is our pre-specified index of clinically significant
change. Secondary outcomes include a reduction of unscheduled service usage and an increase in scheduled
service usage; improved quality of life; and a reduction in mental distress.
Discussion: PEPS therapy has potential as an economical, accessible, and acceptable intervention for people with
personality disorder. The results from this randomised controlled trial will tell us if PEPS therapy is effective and
cost-effective. If so, then it will be a useful treatment for inclusion in a broader menu of treatment options for this
group of service users.
Trial Registration: International Standard Randomised Controlled Trial Number - ISRCTN70660936
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Background
Personality disorder (PD) is a prevalent mental disorder,
affecting over 4% of the general population [1]. People
with personality disorder suffer high levels of distress,
suicide, self-harm, addiction, family breakdown, and
social exclusion. Rendu et al. [2] assessed the costs of
treating people with PD in primary care as £3,094 per
annum, almost twice the costs of people without PD. A
prevalence of PD of almost 5% equates to around 3 mil-
lion people in the UK, costing around £40 million per
annum extra to regular care in primary care alone (at
2002 costs). Furthermore, people with PD place consid-
erable demands upon a range of services, including
emergency departments, social services, and the criminal
justice system. For those who enter outpatient specialist
mental health services, treatment costs are around £135
per treatment session [3], and treatment for people with
PD is often of long duration. People with PD who
offend may enter medium secure services, where the
cost is around £176,000 per person per year [3]. If a
relatively brief and effective treatment can be offered to
a broad spectrum of people with PD dwelling in the
community, this will have the potential to improve the
lives of people with PD, improve access to services, and
also reduce health and non-health service costs.
Systematic reviews of outcomes of psychological treat-
ments for people with PD [4-7] have identified few ran-
domised controlled trials (RCTs). The majority of these
studies are underpowered, most have multiple outcome
measures, and only about one-third measure social func-
tioning, which is agreed to be the most significant clini-
cal problem for this group of patients. We plan to
conduct a well-designed and adequately-powered study
of one promising intervention, namely psycho-education
combined with problem solving (PEPS) therapy, which
has become a popular way of working. Enthusiasm for
its use does not obviate the need for a rigorous evalua-
tion of the effectiveness of PEPS therapy; indeed, if it is
widely used then evidence of effectiveness - or otherwise
- is crucial.
Social problem solving is the process by which an
individual attempts to identify or discover solutions to
specific problems encountered in everyday living [8].
Good social problem solving skills help people to cope
with life’s stressors, particularly those with an interper-
sonal component [9]. Impairment in social functioning
is a key component of PD [10-12], hence the emphasis
on social functioning that underpins problem solving
therapy is highly relevant to the treatment of PD. Using
the Social Problem Solving Inventory-Revised (SPSI-R)
[13], we have found that people with PD, both commu-
nity adults presenting for treatment and detained offen-
ders with PD, report greater impairment on all SPSI-R
scales compared to a sample of mature students [9].
This information suggests that social problem solving
therapy may benefit people with PD.
Meta-analyses have shown problem solving therapy to
be effective in improving a range of mental and physical
health problems [14-16]. This therapy has not been eval-
uated with people with PD, nonetheless it is suited to
this group because the focus is upon improving social
functioning and reducing personal distress. These out-
comes are considered to be of paramount importance in
the treatment of PD [17]. Furthermore, the aim in ther-
apy is to help people recognise both their strengths and
limitations and work with these to learn new skills that
will enable them to cope more effectively with life’s pro-
blems. People with PD have different trait profiles and
different problem solving deficits [18], and problem sol-
ving therapy is sufficiently flexible to accommodate
these differences. It helps clients to adopt a more realis-
tically positive orientation to problem solving, cope bet-
ter with the negative emotions that hinder effective
problem solving, develop a positive problem orientation,
and adopt a rational problem solving style that will lead
to outcomes that improve social functioning and reduce
distress.
Engaging people with PD in treatment is a major chal-
lenge [19,20]. The social problem solving approach
enhances engagement by offering an accessible frame-
work for change (i.e., the approach appeals to common
sense), supporting people in the experience of successful
problem solving (i.e., increasing the likelihood of rein-
forcement of the developing skills), and encouraging
independence rather than reliance on therapy (i.e., pro-
moting self-efficacy). Furthermore, PEPS therapy has a
preliminary psycho-education component which aims to
educate, build rapport, and motivate people for problem
solving therapy [21]. Personality disorders and their
impact are discussed in a collaborative dialogue and
problems that may be worked upon in group sessions
are identified.
PEPS therapy has been evaluated with community
adults with PD in a Phase 2 exploratory trial [22]. At
the end of treatment, compared to a wait-list control
group, those treated with PEPS therapy showed better
social functioning, as measured by the Social Function-
ing Questionnaire [23]. All aspects of social problem
solving improved over the course of PEPS therapy, and,
after controlling for baseline level of social functioning,
the most important predictor of improvement in social
functioning was a reduction in negative problem orien-
tation, i.e., people felt less threatened by problems and
more confident in their ability to solve them [24].
This exploratory study has been identified as impor-
tant in four ways [25,26]. First, the intervention was
brief and hence is likely to be more acceptable to many
patients than lengthier interventions; this decreases the
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likelihood of drop-out and may also be more acceptable
to services with limited resources. Second, PEPS therapy
was delivered in clinical settings, hence its likely effec-
tiveness in everyday practice was indicated. Third, PEPS
therapy was offered to people with any PD or combina-
tion of PDs, so it was inclusive rather than exclusive.
Fourth, PEPS therapy was delivered by non-specialist
staff, hence it would be possible to deliver it relatively
cheaply.
Overall, PEPS therapy has the potential to contribute to
the UK National Health Service’s (NHS) QUIPP agenda
(Quality, Improvement, Productivity and Prevention): it
is a brief, innovative intervention in which staff can easily
be trained and which could be made widely available to
people with personality disorder at a stage where preven-
tion of deterioration is possible. However, a definitive
evaluation now needs to be conducted. A trial will permit
investigation of aspects of the therapy about which there
is currently no information. First, a longer-term follow-
up is necessary to provide information about the sustain-
ability of gains made during treatment. Second, a cost-
effectiveness evaluation of the intervention is required.
Third, there is a need to gather information about the
respective contributions of psycho-education and social
problem solving therapy. We are now conducting a
Phase 3 definitive randomised controlled trial to consoli-
date and extend our knowledge about the effectiveness of
PEPS therapy for people with personality disorder (see
http://www.peps-trial.co.uk). If improvements in social
functioning can be definitively shown to result from ther-
apy and be sustained over time (72 weeks post-randomi-
sation), then this relatively brief intervention could be
used more widely across the NHS.
Study Aims
1. To conduct a randomised controlled trial to evaluate
the effectiveness of PEPS therapy compared with treat-
ment as usual in improving social functioning in com-
munity adults with personality disorder.
2. To assess the costs and cost-effectiveness of PEPS
therapy compared with treatment as usual.
3. To examine intermediate change, specifically the
impact of psycho-education on the therapeutic relation-
ship, and the impact of social problem solving therapy
on social problem solving skills.
5. To conduct a qualitative investigation of the appli-
cation of PEPS therapy in practice to identify the views
of participants.
Study Hypotheses
Our primary hypothesis is that, compared with those in
treatment-as-usual, those in PEPS therapy will show a
greater improvement in social functioning post-therapy
and at follow-up 72 weeks post-randomisation.
Secondary hypotheses are that, compared with those in
treatment-as-usual, those in PEPS therapy will show the
following changes both immediately after therapy and at
follow-up: (a) a greater reduction in receipt of unsched-
uled services; (b) a greater increase in receipt of sched-
uled services; (c) a greater improvement in quality of
life; (d) a greater improvement in referrers’ ratings of
functioning; (e) a greater reduction in anxiety and
depression; and (f) improvement on client-ratings of
self-identified three key problems. Regarding intermedi-
ate changes, we hypothesise that, compared with those
in treatment-as-usual, those in PEPS therapy will show:
(a) better therapist alliance after psycho-education; and
(b) a greater improvement in social problem solving at
end of therapy. We also expect PEPS therapy to show
an acceptable level of cost-effectiveness, based on
thresholds that appear to guide National Institute for
Clinical Excellence (NICE) recommendations.
Method
Design
This is a pragmatic, two-arm, multi-centre, parallel, ran-
domised controlled clinical trial.
Ethics
Approval for the research was given by the South East
Wales Research Ethics Committee - Panel C (Ref: 09/
WSE03/48) and from the Research and Development
(R&D) departments of the participating NHS Trusts:
Central and North West London NHS Foundation
Trust (24195/LNW); Cwm Taf Health Board (CT/039/
09); Tees, Esk and Wear Valleys NHS Foundation Trust
(24195/CDTV).
Participants
The target population is community-dwelling adults with
one or more PD diagnoses, as identified by the Interna-
tional Personality Disorder Examination [27]. Inclusion
criteria are: Living in the community (including residen-
tial or supported care settings); presence of one or more
personality disorder; aged 18 or over; proficiency in spo-
ken English, assessed if necessary by the Basic Skills
Agency ‘Fast Track 20 Questions’ [28]; capacity to pro-
vide informed consent. Exclusion criteria are: Primary
diagnosis of functional psychosis; insufficient degree of
literacy, comprehension or attention to be able to engage
in trial therapy and assessments; currently engaged in a
specific programme of psychological treatment for per-
sonality disorder or likely to start such treatment during
the trial period; currently enrolled in any other trial.
Sample size
The sample size was calculated on the basis of the pri-
mary hypothesis. In the exploratory study [22], those
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referred to PEPS had a greater improvement in social
functioning at 6 month follow-up equivalent to 1.05
points on the SFQ. However, a number of people
received PEPS who were not included in the trial (e.g.,
the wait-list control) and, for this larger sample (N =
93), the mean pre-post- treatment difference was 1.79
(pre-treatment mean = 13.85, SD = 4.21; post-treatment
mean = 12.06, SD = 4.21). (Note: a lower SFQ score is
more desirable). This difference of almost 2 points
accords with other evidence that this is a clinically sig-
nificant and important difference [29]. A reduction of 2
points or more on the SFQ at 1 year follow-up in an
RCT of cognitive behaviour therapy in health anxiety
was associated with a halving of secondary care appoint-
ments (1.24.vs 0.65), a clinically significant reduction in
the Hospital Anxiety and Depression Scale (HADS [30])
Anxiety score of 2.5 (9.9 vs 7.45) and a reduction in
health anxiety (the main outcome) of 5.6 points (17.8 vs
12.2) (11 is a normal population score and 18 is patho-
logical) [29]. These findings suggest that improvements
in social functioning may accrue over 1 year, hence we
expect to find a greater magnitude of response at the
72 week follow-up than we did in the exploratory trial.
Therefore, we have powered this trial to be able to
detect a difference in SFQ score of 2 points. SFQ stan-
dard deviations vary between treatment, control, and
the wait-list samples, ranging from 3.78 to 4.53. We
have based our sample size estimate on the most con-
servative (i.e., largest) SD. To detect a mean difference
in SFQ score of 2 point (SD = 4.53) at 72 weeks with a
two-sided significance level of 1% and power of 80%
with equal allocation to two arms would require 120
patients in each arm of the trial. To allow for 30% drop
out, 170 will be recruited per arm, i.e., 340 in total. We
have considered the need to take clustering effects by
therapy group into account. In this study, as in the
pilot, participants are individually randomised to the
treatment arms, and the observed SD of the response in
the intervention arm automatically includes the effect of
the clustering by therapist. The analysis will take
account of this by using a hierarchical model to allow
explicit estimation of the between therapy group
variance.
Recruitment
To recruit the required number (N = 340), we estimated
that we need to approach twice as many people (N =
680). This estimate is based upon the exploratory trial,
in which 464 potential participants were approached to
be invited to participate; of these, 316 (68%) volunteered
to participate; 255 (55%) turned up for the assessment
interview; 241 (52%) met the criteria and hence were
available to be randomised. A recruitment flow chart is
presented in Figure 1.
Three sites are participating in the trial. Each of the three
sites needs to refer approximately 230 people to the project
over 26 months (approximately 106 per year). Based on
information about the sites, this was considered to be feasi-
ble. In West London, the two local Mental Health Trusts
from which we are recruiting serve a population of 1.7 mil-
lion people, with potentially 74,800 people with personality
disorder. In 2007, one of the five boroughs received 80
referrals of people with personality disorder who were
motivated to receive psychological treatment for their dis-
order. New specialist services were planned for 2009 in two
of the other boroughs and similar rates of referral to these
new services were expected. Cwm Taf NHS Trust serves a
population of 330,000 with potentially 14,520 people with
personality disorder. In 2007, there were 4,173 referrals per
annum across two Community Mental Health Teams
(CMHTs) and two crisis teams. A retrospective audit of
randomly selected current case notes (N = 109) found that
between 8 and13% of people seen by one CMHT met the
DSM-IV criteria for borderline personality disorder. There-
fore, an estimated 333 to 542 of the people annually
referred to mental health services were expected to meet
the diagnostic criteria for borderline personality disorder.
Assuming that this figure represents between 30% and 60%
of the population with personality disorders, it can be esti-
mated that an additional number of between 133 and 217
people meet the criteria of a personality disorder other
than borderline. Tees, Esk and Wear Valley NHS Founda-
tion Trust serves a total population of 1.4 million across
County Durham, the Tees Valley and North East Yorkshire.
One existing advanced practitioner service for personality
disorder covering a population of 100,000 received approxi-
mately 50 referrals per year, primarily from CMHTs, of
individuals likely to benefit from psychological intervention.
This service was planning to expand its remit to the larger
area of North Durham (300,000 population) and Teesside
(500,000 population), hence it was expected that an
expanded service would receive up to 400 referrals annually
for all personality disorders by the study start date, requir-
ing a referral rate of the study of less than 25% to meet the
target.
Randomisation and blinding
Randomisation is based on a computer generated
pseudo-random code using random permuted blocks of
randomly varying size, created by the Nottingham Clini-
cal Trials Unit (CTU) in accordance with their standard
operating procedure and held on a secure server. The
randomisation is stratified by recruiting centre and sex
of participant. Access to the sequence is confined to the
Trial Data Manager. Researchers access the treatment
allocation for each participant by means of a remote,
internet-based randomisation system developed and
maintained by the Nottingham CTU. The sequence of
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treatment allocations will be concealed until interven-
tions have all been assigned and recruitment, data col-
lection, and all other trial-related assessments are
completed. The trial is single-blind, with participants
and local investigators administering the interventions
being aware of the treatment allocation. Outcome mea-
sures are administered in a blinded fashion by research-
ers to minimise the effects of lack of blinding.
Interventions
Psycho-education combined with problem solving (PEPS)
therapy is a complex cognitive-behavioural intervention
that integrates individual and group therapies. Psycho-
education is an individual 4-session collaborative dialogue
designed to build a rapport with patients, inform them
about their personality disorder, discuss its effects on
interpersonal relationships and social functioning, and
enhance motivation for therapy [21]. In psycho-education,
participants are taken through their personality disorder
diagnoses, as identified via a structured clinical assess-
ment. Participants are asked what problems they experi-
ence in relation to their personality disorder and they are
then guided to specify problems which are then prioritised
to be addressed in the problem solving therapy sessions.
Recruitment 
Expect to Approach 
N = 680 
Screening 
Expect to Screen 
N = 374 
Eligible for 
Randomisation 
Randomisation 
N = 340 
PEPS 
N = 170 
TAU 
N = 170 
Follow-Up Post-
Treatment and at 4 
Months 
Final Follow-Up at 
72 Weeks 
Primary Outcome 
Figure 1 Recruitment Flow Diagram.
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Problem solving therapy is a 12-session group inter-
vention designed to teach people strategies for solving
interpersonal problems [9]. Participants are encouraged
to learn the process of a) identifying negative feelings
and using these as a cue for initiating the problem sol-
ving process; b) defining their problem clearly and accu-
rately; c) setting specific goals for change; d) generating
solution options; e) considering the consequences of
each option; and f) selecting potentially effective options
and organising these into a means-end action plan. Par-
ticipants are then expected to implement the action
plan and are offered individual support sessions to help
with implementation. Progress with the action plan is
reviewed in the next group session.
Assessments
Screening
Screening for personality disorder is via the Interna-
tional Personality Disorder Examination (IPDE) [27].
This is a 99-item, semi-structured interview that allows
both diagnostic and dimensional scores to be extracted
for each personality disorder according to either DSM
or ICD criteria.
Primary outcome
The primary outcome is social functioning, measured by
the Social Functioning Questionnaire (SFQ) [23]. The
SFQ is an 8-item self-report scale, with items covering
the domains of home, work, leisure, and relationships.
Respondents rate the extent to which they have experi-
enced problems in each area over the last two weeks on
a scale from 0 to 3. SFQ scores correlate well with mea-
sures of psychiatric distress and are stable over time. A
reduction (i.e., an improvement) of 2 points or more on
the SFQ at follow up 72 weeks post-randomisation is
our specified clinically significant change.
Secondary outcomes
Measures of a number of secondary outcomes are listed
below.
Receipt and cost of services (Client Service Receipt
Inventory; CSRI [31]). One measure used to capture ser-
vice use is the CSRI, which records health and social
care, criminal justice, informal care services, employ-
ment and benefits as reported by the participant. This
information will be used in the cost-effectiveness analy-
sis. Service use will be assessed for the period 6 months
prior to baseline, and at three points after treatment
(immediately after, at 4 months and at 72 weeks). The
long-term follow up is necessary to pick up potential
improvement overall, rather than capture a temporary
increase at the end of treatment.
Scheduled and unscheduled service use (Record
Check) People with PD are often long-term users of ser-
vices, but they can be chaotic users of those services.
Hence, one valuable outcome would be a more
systematic use of the services available. We hope to find
a reduction of unscheduled service usage and an
increase in scheduled service usage. Data on mental
health service use, Emergency Department attendances
and hospital admissions will be collected through a
review of mental health service and GP records to ascer-
tain use of scheduled and unscheduled services. Service
use data will be collected retrospectively for the duration
of involvement in the trial, from baseline to 72 week fol-
low-up.
Quality of life (EuroQOL; EQ-5D) [32]. The EQ-5D is a
health-related quality of life measure and will be used to
generate quality-adjusted life years for use in the eco-
nomic evaluation. The EQ-5D will be administered
before and after treatment, and again at 72 week follow-
up.
Referrer’s assessment of problems (change in referrer’s
score on Global Assessment of Functioning; GAF) [33].
The GAF is the standard method for representing a
clinician’s judgment of a patient’s overall level of psy-
chosocial functioning and will be rated by the referrer.
Anxiety and depression (Hospital Anxiety and Depres-
sion Scale; HADS) [30]. A reduction in mental distress
is an important outcome for service users [17], therefore
anxiety and depression will be measured using the 14-
item HADS.
Client’s assessment of problems (i.e., specific treatment
targets for individuals). A focus on the problems most
relevant to the client is considered important [34]. Parti-
cipants will be asked to identify their three most impor-
tant problems and rate their severity before and after
treatment.
Intermediate outcomes
Two intermediate outcomes are assessed.
Treatment alliance (Working Alliance Inventory; WAI)
[35]. The WAI examines the development of treatment
alliance, and will be used to assess the effectiveness of
the psycho-education component in developing treat-
ment alliance. The WAI is a 36-item questionnaire that
can be administered to both clients and therapists. Each
item is rated on a 7-point scale and scores are produced
on three factors: the therapeutic bond, the agreement
on goals, and the agreement on tasks.
Social problem solving skills (Social Problem Solving
Inventory-Revised; SPSI-R) [13]. The SPSI-R assesses
the development of social problem solving skills to
examine whether the social problem solving component
improves these skills as expected. The SPSI-R is a 25-
item client self-report questionnaire that measures pro-
blem solving orientation (positive and negative) and pro-
blem solving style (rational, impulsive and avoidant).
Process measures
Information will be gathered regarding the route of
referral, sessions offered, and participants’ attendance.
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Semi-structured interviews will access information about
experiences of therapy, its perceived effects and its per-
ceived limitations. Interviews will also provide an oppor-
tunity to support people after psycho-education, since
some participants report finding this distressing [36].
A flow chart of the procedures in the PEPS trial is
presented in Figure 2.
Analyses
Demographic and other baseline data will be sum-
marised by descriptive statistics (number [N], mean,
standard deviation [SD], median, minimum and maxi-
mum) or frequency tables, stratified by treatment. Mea-
sures of adherence to protocol implementation will be
summarised by descriptive statistics (number [N], mean,
standard deviation [SD], median, minimum and maxi-
mum) or frequency tables, stratified by treatment arm.
Efficacy will be assessed on the full analysis set, defined
as all randomised participants for whom a post-baseline
assessment of the primary endpoint is available, that is,
in accordance with the “intention to treat” (ITT) princi-
ple. The primary efficacy parameter will be the differ-
ence in mean SFQ score between treatment arms,
estimated using a hierarchical regression model with
adjustment for relevant covariates, including centre, sex
and personality disorder classification. Differences in
mean totals of secondary outcomes at 72 weeks from
randomisation will be compared between the two treat-
ment arms, after adjusting for design (centre and sex)
covariates. Analyses will be performed using Stata ver-
sion 11 or above.
The costs of the interventions will be estimated by
combining data on number of sessions provided with
unit costs derived from local data on service expenditure
and activity. These costs will include therapist time,
oncosts, overheads and capital. Costs of other services
will be calculated by combining service use data col-
lected with the CSRI with appropriate unit costs. Costs
will be compared between the two groups, with boot-
strap methods used to generate confidence interval
round the difference due to the expected skewed cost
distribution. Cost-effectiveness will be assessed by com-
bining the cost adapt with outcomes, namely SFQ scores
and Quality-Adjusted Life Years (QALYs). If the costs
for the PEPS arm are less than for TAU and the out-
come better, then it will be the ‘dominant’ intervention.
However, if costs are greater and outcomes better, then
an incremental cost-effectiveness ratio will indicate the
extra costs incurred to achieve an extra unit-improve-
ment in outcome (i.e., a one-point improvement on the
SFQ or one extra QALY). There will be uncertainty
around the point estimates of cost and outcome differ-
ences and this uncertainty will be explored by generat-
ing a large number of cost-outcome combinations using
bootstrapped resample and plotting these on a cost-
effectiveness plane. Cost-effectiveness will be interpreted
using cost-effectiveness acceptability curves. These will
show the probability that PEPS is more cost-effective
intervention than TAU for a range of values placed on a
unit-improvement in outcome. The range of values for a
one-point improvement on the SFQ is unclear, but will
be chosen such that we will be able to observe the
points at which there is at least at 50% and 80% prob-
ability of PEPS being cost-effective. The range of values
for a gain of one QALY is more straightforward as it
appears that the value that informs NICE recommenda-
tions is between £20-30K. Therefore we will use a range
of £0-£100K to produce the curve so as to include this
threshold.
Thematic analysis methods will be used to specify the
nature of treatment-as-usual in terms of what problem
was treated by which service/professional and how. The-
matic analysis methods will be used to identify themes
in participants’ opinions of PEPS therapy and TAU.
Discussion
PEPS therapy has potential as an economical, accessible,
and acceptable intervention for people with personality
disorder. Individual psychoeducation has the potential
to enhance engagement in the group therapy that fol-
lows [21,25], thus addressing the important issue of
treatment non-completion [19,20]. Problem solving ther-
apy, a major component of PEPS, has a good track
record with a range of physical health and mental health
problems [14-16], but its effectiveness has not yet been
examined with personality disorder. Referring to the
PEPS pilot study [22], one commentator noted that the
relatively brief PEPS intervention challenges the notion
that long-term treatment is always necessary for PD:
“The idea that people with personality disorders can
only improve after years of treatment has led to a rela-
tive neglect of this patient group, based on the belief
that they cannot benefit from pragmatic treatment. This
study, along with several others, shows that significant
progress can be made with less expensive and briefer
interventions” [26, p. 121]. There is a recent drive to
evaluate briefer interventions for PD [37]. Another com-
mentator noted that, if the PEPS intervention proves
cost-effective, then this would “not only improve the
evidence base for treatment of personality disorder, but
[...] might also go some way towards challenging the
ambivalence that some healthcare professionals continue
to have about working with people with personality dis-
orders” [25, p. 284]. The PEPS intervention does, there-
fore, have positive potential in a number of ways.
There are, however, challenges to be met in the course
of conducting the trial. We face the potential problem of
drop-out between consent to participate and the start of
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group therapy, since there will be delays caused by wait-
ing for sufficient numbers to accrue in order to start
group treatment. This problem will be exacerbated by
the intensive nature of the assessment procedure which
participants will need to undertake before randomiza-
tion, hence slowing down the accrual of participants
ready for randomization.
There are also limitations that need to be acknowl-
edged. First, this is not a double-blind study design and
so the participants and some of the researchers collect-
ing interim follow-up information will be aware of parti-
cipant allocation. However, the researchers and
statisticians collecting and analysing the follow-up data
will be blind to treatment status. The risk of unblinding
Recruitment & Informed Consent 
Ð 
Screening Interview 
 IPDE, Fast Track 20 Questions (if required) 
Ð 
Baseline Assessment 
EQ-5D, SFQ, CSRI, GAF, HADS, 3 Main Problems, SPSI-R 
Ð 
Ó Randomisation      Ô 
PEPS Therapy Week 0 Treatment as Usual 
Ð  Ð 
One-to-One Intervention 
Up to four weekly individual sessions of psycho-
education conducted by a trained mental health worker 
 
 
 
 
 Ð 
  
Ð  Ð 
First Follow-Up 
HADS, 3 Main Problems, WAI 
 
Semi-structured interview with client by mental health 
worker to identify the effects of psycho-education 
 First Follow-Up HADS, 3 Main Problems, WAI 
Ð  Ð 
Group Intervention 
Twelve group problem solving therapy sessions 
facilitated by trained mental health workers 
 Ð 
Ð  Ð 
Second Follow-Up 
EQ-5D, SFQ, CSRI, GAF, HADS, 3 Main Problems, 
SPSI-R 
 
Semi-structured interview with client by mental health 
worker to identify the effects of problem solving therapy 
 
Second Follow-Up 
EQ-5D, SFQ, CSRI, GAF, HADS, 3 Main Problems, 
SPSI-R 
Ð  Ð 
Third Follow-Up 
CSRI 
 
Contact by clients preferred means to give an update on 
the project 
 
Third Follow-Up 
CSRI 
 
Contact by clients preferred means to give an update on 
the project 
Ð  Ð 
Trial Update 
Contact by clients preferred means to give an update on 
the project 
 
Trial Update 
Contact by clients preferred means to give an update on 
the project 
Ð  Ð 
Final Follow-Up 
EQ-5D, SFQ, CSRI, GAF, HADS, 3 Main Problems, 
SPSI-R, Service Use Record Check 
Semi-structured interview with client by researcher 
about experiences of PEPS therapy 
Week 72 
Final Follow-Up 
EQ-5D, SFQ, CSRI, GAF, HADS, 3 Main Problems, 
SPSI-R, Service Use Record Check 
Semi-structured interview with client by researcher 
about experiences of treatment as usual 
Figure 2 Procedural Flow Diagram.
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researchers will be minimised by instructing participants
and clinical teams not to disclose treatment details at
any stage. Cases of possible unblinding of researchers
will be logged. Second, although this is a pragmatic trial,
there are extensive assessments, necessary for research
purposes, that would likely not be conducted in actual
clinical practice. These assessments may have an impact
on outcome, even without the active treatment that fol-
lows in the treatment arm. This may minimise differ-
ences between arms.
If we overcome potential difficulties and minimise lim-
itations, the results from this randomised controlled trial
will tell us if PEPS therapy is effective and cost-effective.
If it proves to be so, then it will be a useful treatment
for inclusion in a broader menu of treatment options
for this group of service users.
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